We next examined the degree of MAPK pathway inhibition after treatment in tumor cells using an MAPK gene expression signature score based on changes in the MAPK-regulated transcripts (DUSP6, ETV4, ETV5 and SPRY4) in tumor epithelial cells. The gene discussed is SPRY4; the disease is neoplasm.